Anzeige
Mehr »
Login
Mittwoch, 04.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 16.11.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
16.11.Intellia Therapeutics, Inc.: Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression ...103Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater...
► Artikel lesen
16.11.Procaps Group, S.A.: Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing179MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) ("Procaps" or the "Company"), announced today that, on November 13, 2024, the Company received...
► Artikel lesen
16.11.BYD Energy Storage: BYD emphasizes strong partner collaboration in the energy storage market during partner conference1.242SHENZHEN, China, Nov. 16, 2024, expands the partner program for BYD Energy Storage solutions. As part of the program, BYD held a partner conference at the BYD headquarters in November 2024, in which...
► Artikel lesen
16.11.Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab427SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the...
► Artikel lesen